Pharmaceutical Investing MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma
Pharmaceutical Investing MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 in Alcohol Use Disorder and Withdrawal
Pharmaceutical Investing Eloxx Pharmaceuticals Announces Uplisting to Nasdaq and Pricing of $50 Million Public Offering of Common Stock
Pharmaceutical Investing MediciNova Announces Collaboration with the University of Sydney Concord Cancer Centre
MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
Pharmaceutical Investing MediciNova Announces Closing of Underwritten Public Offering of Common Stock
Heritage Mining Ltd. Announces Closing of the Second and Final Tranche of its Non-Brokered Private Placement of Units and Flow-Through Units
